Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
AssigneeWest China Hospital, Sichuan University
InventorXiao-Qing Qiu
Life of this patent
Estimating the term…
Abstract
The present invention relates to molecules that are capable of killing cells. The molecules comprise a targeting agent and a channel-forming moiety. The molecules may be polypeptides. The present invention also relates to polynucleotide sequences encoding the polypeptides of the invention. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is an antibody. Methods of treatment by administering the molecules of the present invention are also provided.
Claims49
A molecule for treating a cell proliferative disorder comprising a targeting agent covalently attached to a channel-forming moiety.
The polypeptide of claim 12, wherein said antibody is an antibody or engineered antibody variant.
The polypeptide of claim 13, wherein said antibody or engineered antibody variant is against Epstein-Barr virus gp350/220 envelope glycoprotein.
A polypeptide for the treatment of a cell proliferative disorder comprising an targeting moiety selected from the group consisting of reconstituted antibody mimetics derived from engineered antibody variants against Epstein-Barr virus gp350/220 envelope glycoprotein and a channel-for mning domain of colicin.
A method of treating a subject having a cell proliferative disorder, comprising:
- administering to said subject an effective amount of a polypeptide comprising a targeting agent and a channel-forming moiety;
- thereby treating said subject.
Amolecule comprising a targeting agent covalently attached to a channel-forming moiety, wherein the molecule has the ability to decrease or inhibit cell proliferation in a cell in need thereof.
Apolypeptide consisting essentially of the amino acid sequence of SEQ ID NO:1.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 7.
A polypeptide comprising the amino acid sequence of SEQ ID NO:11.
Dependencies are inferred from the claim text.